The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a unique Healthcare Common Procedure Coding System (HCPCS) code or J-Code to Fidia Pharma’s HYMOVIS® highly viscoelastic, non-crosslinked hydrogel to treat knee osteoarthritis pain. The reimbursement code is effective January 2017.
The product was launched in the U.S. at AAOS 2016.
Other viscosupplements in 2016 news include:
- AmnioVisc
- CINGAL
- GELSYN-3 HA
- SUPARTZ-FX
Sources: Fidia Pharma USA Inc.; ORTHOWORLD Inc.
The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a unique Healthcare Common Procedure Coding System (HCPCS) code or J-Code to Fidia Pharma's HYMOVIS® highly viscoelastic, non-crosslinked hydrogel to treat knee osteoarthritis pain. The reimbursement code is effective January 2017.
The product was launched in the U.S. at AAOS...
The U.S. Centers for Medicare & Medicaid Services (CMS) assigned a unique Healthcare Common Procedure Coding System (HCPCS) code or J-Code to Fidia Pharma’s HYMOVIS® highly viscoelastic, non-crosslinked hydrogel to treat knee osteoarthritis pain. The reimbursement code is effective January 2017.
The product was launched in the U.S. at AAOS 2016.
Other viscosupplements in 2016 news include:
- AmnioVisc
- CINGAL
- GELSYN-3 HA
- SUPARTZ-FX
Sources: Fidia Pharma USA Inc.; ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.